Hyperkalemia Due to Nafamostat Mesylate
- 9 March 1995
- journal article
- letter
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 332 (10) , 687
- https://doi.org/10.1056/nejm199503093321018
Abstract
Nafamostat mesylate (6-amidino-2-naphthyl p-guanidinobenzoate, dimethanesulfonate; molecular weight, 540) is a synthetic serine protease inhibitor that is widely used to treat acute pancreatitis in Japan.1 The drug and its metabolites reversibly inhibit amiloride-sensitive sodium conductance of renal cortical collecting ducts,2,3 thus impairing urinary potassium excretion. Hyperkalemia could therefore develop in patients receiving this drug.Keywords
This publication has 5 references indexed in Scilit:
- Fluid, Electrolyte and Acid-Base PhysiologyCritical Care Nursing Quarterly, 1994
- Mechanisms of the hyperkalaemia caused by nafamostat mesilate: effects of its two metabolites on Na+ and K+ transport properties in the rabbit cortical collecting ductBritish Journal of Pharmacology, 1994
- Effect of nafamostat mesilate on Na+ and K+ transport properties in the rabbit cortical collecting ductBritish Journal of Pharmacology, 1993
- Trimethoprim-Induced Hyperkalemia in a Patient with AIDSNew England Journal of Medicine, 1993
- Pharmacological Studies of FUT-175, Nafamostat Mesilate V. Effects on the Pancreatic Enzymes and Experimental Acute Pancreatitis in RatsThe Japanese Journal of Pharmacology, 1986